Phathom Pharmaceuticals (PHAT) reported a strong first quarter for 2026, with net revenues reaching $58.3 million, marking a remarkable 104% year-over-year increase. The company attributed this growth to a significant rise in prescription volumes for its gastroenterology drug, VOQUEZNA, which reached 1.35 million cumulative prescriptions. Notably, covered prescriptions surged by 91% year-over-year, driven by the introduction of a cash pay option for Medicare patients.

This robust performance highlights Phathom’s effective sales strategy, as the company expanded its sales force to over 290 representatives and maintained a gross margin of approximately 80%. Management reaffirmed its 2026 revenue guidance of $320 million to $345 million, while also indicating a path to operating profitability by fiscal Q3. The ongoing success of VOQUEZNA positions Phathom favorably against competitors, particularly as it prepares for upcoming clinical trial data.

For market professionals, the key takeaway is Phathom’s sustained momentum in prescription growth, which could signal a strong trajectory for future revenue and profitability, particularly as it capitalizes on its expanding market share in gastroenterology.

Source: fool.com